Adbry® Clinical Results | Clearer Skin & Long-Term Itch Relief

See how Adbry^® defines eczema relief for you

It can be frustrating when your is still not under control. Adbry works inside the body to help get clearer skin and control the unbearable itch for the long-term. Adbry was used in 2 clinical trials for up to 1 year, and 1 trial for up to 8 months. Talk to your healthcare professional to see if Adbry is right for you.

How was Adbry studied in clinical trials?

Adbry was studied in 3 separate clinical trials of almost 2,000 adults aged 18 and older with moderate-to-severe (). Adults in the trials injected 2 prefilled syringes every other week.

TRIAL 1: 601 adult patients used Adbry; 197 used

TRIAL 2: 577 adult patients used Adbry; 193 used

TRIAL 3: 243 adult patients used Adbry + ; 123 used +

Clearer skin was measured in 2 ways:

The percentage of adult patients who saw clear or almost clear skin
The percentage of adult patients who saw a 75% or better improvement in skin

Trial 3: Adbry + topical corticosteroids vs placebo + topical corticosteroids

Clearer skin and less itch

243 adults used Adbry every other week + as needed;
123 adults used every other week + as needed.

CLEAR OR ALMOST CLEAR SKIN

Infographic showing that 40% of adults achieved almost clear skin after 4 months using Adbry® versus 27% using placebo, and 89% maintained clear or almost clear skin after 8 months.

75% OR BETTER IMPROVEMENT IN SKIN

Infographic showing that 56% of adults achieved 75% or better skin improvement after 4 months using Adbry® versus 37% using placebo, and 92% maintained this improvement after 8 months.

Additional Results

After 4 months, almost 50% of adults experienced significantly less itch (vs 35% of adults using ).

Trial 1: Adbry alone vs placebo

Clearer skin and less itch

601 adults used Adbry every other week; 197 used every other week.

At 4 months of Adbry alone:

16% of adults saw clear or almost clear skin (vs 7% of adults using )
25% of adults saw a 75% or better improvement in skin (vs 13% of adults using )

20% of adults experienced less itch (vs 10% of adults using ).

TRIAL 1

Infographic showing that after one year, 51% of adults maintained clear or almost clear skin, and 60% of adults maintained a 75% or better improvement in skin while using Adbry.

Trial 2: Adbry alone vs placebo

Clearer skin and less itch

577 adults used Adbry every other week; 193 used every other week.

At 4 months of Adbry alone:

21% of adults saw clear or almost clear skin (vs 9% of adults using )
33% of adults saw a 75% or better improvement in skin (vs 10% of adults using )

25% of adults experienced less itch (vs 9% of adults using ).

TRIAL 2

Infographic showing that after one year in Trial 2, 60% of adults maintained clear or almost clear skin, and 57% of adults maintained a 75% or better improvement in skin while using Adbry.

Badge: Fast itch relief in just one week

At the end of Week 1, adults taking Adbry achieved a 9% improvement* in itch versus 3% for those who did not receive Adbry.

*Based on data gathered from Trials 1 and 2 (1,556 patients combined).

Across Trials 1, 2, and 3, more adults using Adbry saw a

Graphic showing 90% or better improvement in skin across trials 1, 2, and 3 for adults using Adbry compared to placebo.

in their skin compared to those using .

Adbry for children (ages 12-17)

If you have a child with moderate-to-severe , your role as a caregiver is an important one. A big part of that is helping to navigate their treatment options. It may help to know that Adbry has been studied in children (ages 12-17) to ensure its safety and test its ability to achieve clearer skin and less itch.

How was Adbry studied in children (ages 12-17)?

Pediatric patients were treated using Adbry alone, without . The clinical trial included 192 patients aged 12-17 with moderate-to-severe , and they were injected with 1 prefilled syringe every other week after their initial loading dose.

TRIAL: 98 children aged 12-17 used Adbry; 94 used

Clearer skin was measured in 2 ways:

The percentage of pediatric patients who saw clear or almost clear skin
The percentage of pediatric patients who saw a 75% or better improvement in skin

Pediatric Trial: Adbry alone vs placebo

Clearer skin and less itch at 4 months

21% of pediatric patients taking Adbry saw clear or almost clear skin (vs 4% for )
>5X
as many patients

29% of pediatric patients taking Adbry saw a 75% of better improvement in skin (vs 6% for )
>4X
as many patients

23% of pediatric patients taking Adbry experienced less itch (vs 3% for )
>7X
as many patients

Keep learning about Adbry:

Adbry side effects

See the safety information

How to use Adbry

Watch the video

Frequently asked questions

Get Adbry answers

IMPORTANT SAFETY INFORMATION AND INDICATION

Read more Collapse

What should I discuss with my healthcare provider before starting ADBRY?

Tell your healthcare provider about all your medical conditions, including if you:

have eye problems.
have a parasitic (helminth) infection.
are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with ADBRY.
are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use ADBRY?

See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes and autoinjectors.
Use ADBRY exactly as prescribed by your healthcare provider.
Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
ADBRY comes as a single-dose prefilled syringe with needle guard or as an autoinjector.
ADBRY is given as an injection under the skin (subcutaneous injection).
If your healthcare provider decides that you or a caregiver can give the injections of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. Do not try to inject ADBRY until you have been shown the right way by your healthcare provider. In children 12 years of age and older, it is recommended that ADBRY be given by or under supervision of an adult.
If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
If you inject too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

What are the possible side effects of ADBRY?

ADBRY can cause serious side effects, including:

Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:
- breathing problems
- itching
- skin rash
- swelling of the face, mouth, and tongue
- fainting, dizziness, feeling lightheaded (low blood pressure)
- hives

Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

Upper respiratory tract infections
Eye and eyelid inflammation, including redness, swelling, and itching
Injection site reactions
High count of a certain white blood cell (eosinophilia)

These are not all the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is ADBRY?

ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.
It is not known if ADBRY is safe and effective in children under 12 years of age.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.

Please see full Prescribing Information, including Patient Information and Instructions for Use.